Abstract

Disclosed are in the present application a pharmaceutical complex formulation with controlled drug release comprising linagliptin or a pharmaceutically acceptable salt thereof and metformin or a pharmaceutically acceptable salt thereof.

IPC Classes  ?

• A61K 9/24 - Layered or laminated unitary dosage forms
• A61K 9/20 - Pills, lozenges or tablets
• A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2)
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

Disclosed is a pharmaceutical composition in a liquid form containing efinaconazole.

IPC Classes  ?

• A61K 9/08 - Solutions
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61P 31/10 - Antimycotics

Abstract

Zingiber officinale Rosc. as an active ingredient and a method thereof, and more specifically, to a pharmaceutical composition having an inhibitory effect on monocyte adhesion in intestinal epithelial cells, an effect of inhibiting the production of inflammatory cytokines, an effect of ameliorating colitis in an animal model of dextran sodium sulfate (DSS)-induced colitis, and an effect of ameliorating Crohn's disease in an animal model of 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced Crohn's disease.

IPC Classes  ?

• A61K 36/285 - Aucklandia
• A61K 36/9068 - Zingiber, e.g. garden ginger
• A61K 36/185 - Magnoliopsida (dicotyledons)
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A61K 36/28 - Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

The present invention relates to a nail lacquer composition containing at least one antifungal agent as a pharmacologically active ingredient. The present invention has an excellent penetrating effect of a drug in skin areas where the drug is applied because of needing treatment and, specifically, in fingernails by containing a polymer material which forms a specific film, and a penetration enhance, is convenient for management after locally applying the drug to a treatment site, and has excellent storage stability of the drug.

IPC Classes  ?

• A61K 31/4412 - Non-condensed pyridinesHydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
• A61Q 17/00 - Barrier preparationsPreparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
• A61Q 3/02 - Nail coatings
• A61K 8/81 - Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
• A61K 8/49 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
• A61K 31/4418 - Non-condensed pyridinesHydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61P 31/10 - Antimycotics
• A61K 9/70 - Web, sheet or filament bases
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61K 47/38 - CelluloseDerivatives thereof